Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VD (Velcade, Dexamethasone) Induction Followed by HDT With ASCT and thalidomide maintenance for Newly Diagnosed MM - Sequential VAD and VD Followed by HDT With ASCT and Thalidomide Maintenance for NDMM

Ochanomizu blood study committee0 个研究点目标入组 60 人开始时间: 2009年11月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. History of allergic reaction attributable to compounds containing boron or mannitol 2. Known hypersensitivity to thalidomide or dexamethasone 3. Peripheral neuropathy or neuropathic pain Grade 2 or higher as defined by NCI CTCAE version 3 4. Uncontrolled or severe cardiovascular disease, including MI within 6 months of enrollment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis 5. Acute severe infection requiring antibiotic therapy 6. Previous cancer history (except in situ carcinoma of cervix or basal cell cancer of skin) 7. Pregnancy or breastfeeding 8. Active ulcer detected by gastroscopy (gastroscopy is not routine in all patients, only to patients with symptoms of ulcer disease and/or history of previous ulcer therapy and/or physician's discretion) 9. Previous renal transplantation 10. Recurrent deep vein thrombosis or pulmonary embolism 11. Uncontrolled diabetes mellitus 12. Receipt of extensive radiation therapy within 4 weeks ((Extensive means RT to more than 2 anatomic sites).

发起方

Ochanomizu blood study committee